EpiFemCare project mentioned in German national newspaper ‘Die Zeit’.
GATC Biotech has been developing sequencing and bioinformatics solutions for over twenty years in order to help researchers accelerate their research projects. 2006 we were the first to offer multiplatform sequencing approaches in Next Generation Sequencing.
In 2007 GATC Biotech launched human genome sequencing service at BIO-Europe 2007 partnering conference. Since 2010, GATC Biotech serves as a sequencing service provider for the International Cancer Genome Consortium (ICGC).
For the ICGC Initiative GATC Biotech has sequenced more than
The results were recently published in Nature (Jones, David T. W. et al., Nature 488, 100–105, 02 August 2012)
Prof. Dr. Peter Lichter, Director DKFZ, Heidelberg (Project coordinator of the ICGC Initiative)
"GATC Biotech proved itself to be a reliable sequencing partner in the pilot phase of the project and so we are now continuing that successful collaboration.”
In 2012 GATC Biotech has started the collaborative research project EpiFemCare to uncover new methods for screening, diagnosing and personalising treatment of breast and ovarian cancers. The project uses cutting edge technologies from the field of epigenetics to develop blood tests for highly sensitive cancer detection.
GATC Biotech manages for the EpiFem Care project sample processing, i.e. the DNA isolation from serum and the reduced representation bisulfite sequencing from serum derived DNA.
Prof. Dr. Martin Widschwendter, Head of the Department for Gynaecological Oncology, University College London (Coordinator of the EpiFemCare project)
“This research project brings together a powerful partnership of major European cancer centres and companies operating state-of-the-art technologies to make a real change for women with breast and ovarian cancers.”
More selected applications in the field of Human Research: